Based on success studies of coagulation factor inhibitors from hematophagous organisms in tumor cell lines (Tuszynski et al., 1987; Hembrough et al., 2003) and due to Amblyomin-X’s similarity with TFPI, a viability assay was performed with several tumor cell lines to evaluate the antitumor activity of this molecule. Here, TFPI is linked to neoplasm.